News

GLEN ALLEN, Va. — Star Scientific, Inc. (NASDAQ: STSI), today announced that John Isner, the top-ranked American player on the ATP World Tour, will be the next brand ambassador for the Company’s Anatabloc® dietary supplement for anti‐inflammatory support. Isner is the second brand ambassador for Anatabloc®, joining PGA Tour champion Fred Couples.

Since the start of his professional career in 2007, after completing four years at the University of Georgia, Isner has been recognized as one of the rising stars of American tennis. Some of Isner’s accomplishments include winning five ATP tour titles, leading the United States to the 2012 Davis Cup semifinal, winning the longest match in tennis history at Wimbledon in 2010, defeating world #1 Novak Djokovic and former world #1 Roger Federer during the first half of the 2012 season, and reaching the quarterfinals of the 2012 London Olympics. Isner also broke into the ATP top 10 during the 2012 season and is often considered a future Grand Slam contender.

Isner recently learned about the benefits of Anatabloc® and started using the supplement to help provide anti-inflammatory support naturally. “Anatabloc has allowed me to stay on the court longer and in the gym longer, while at the same time helping with the recovery process. I simply do not feel as sore and fatigued as I have in the past,” Isner stated.

“We are extremely proud to have John teaming up with Anatabloc®, a product that is becoming increasingly popular in the world of professional athletics,” said Isner’s manager, Sam Duvall, Vice President at Lagardere Unlimited Tennis.

“John is a phenomenal athlete who has become a giant in the world of tennis,” stated David Dean, Vice President of Sales and Marketing for Star Scientific, Inc. “He will be a tremendous partner for Star Scientific as he helps spread the word about Anatabloc®, and the difference it is making in his game. We are excited to have him as an Anatabloc® brand ambassador. Sales continue to grow and we are looking forward to a great year ahead.”

Isner’s decision to become an Anatabloc® brand ambassador coincides with the Company’s results of testing from HFL Sport Science, one of the leading organizations in doping control and research. HFL Sport Science batch tested Anatabloc® for the presence of a wide range of more than 147 prohibited substances using HFL’s ISO17025 accredited nutritional supplement screens. The testing found Anatabloc® to contain no banned substances.

PGA Tour Professional Fred Couples, the Company’s first Anatabloc® Brand Ambassador, continues in his role as a principal spokesman for the product, and is excited to see Anatabloc® growing and spreading into different areas of professional athletics. Couples will be inducted into the World Golf Hall of Fame in 2013 and will serve as Captain of The 2013 Presidents Cup.

Paul L. Perito, Chairman, COO, and President of Star Scientific, Inc. commented, “We are proud to have both Fred and John on board. We are hopeful that their success with the product will encourage other athletes and active individuals to try Anatabloc® and spread the word. Now that HFL Sport Science has concluded its vigorous testing of Anatabloc®, we look forward to expanding our presence and helping all types of athletes and active individuals reach their full potential.”

Anatabloc® can be purchased at GNC Stores nationwide, and at GNC.com and anatabloc.com.

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.